Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

RT-PCR Technology Provides New Accurate Diagnostic Test For Swine H1N1 Influenza
A new, easy-to-perform method for detecting both seasonal influenza A virus and the emerging H1N1 swine-derived influenza A virus in human clinical samples offers a fast, sensitive, and cost-effective diagnostic test that runs on standard laboratory equipment. This timely and broadly applicable molecular technique is described in an article published online ahead of print in Vector-Borne and Zoonotic Diseases, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at http://www.liebertpub.com/vbz.
generic viagra online
Personal Exposure Monitors Show Pharmacy Workers Inhale Drugs When Using Air Pressure-Activated Dispensing Machines
AlburtyLab released a report on its comprehensive evaluation of health risks for workers in pharmacies using air pressure-activated drug dispensing machines. The study tested pharmacy workers wearing personal exposure monitors (PEMs) while using the two leading types of air pressure-activated dispensing technologies - the McKesson/Parata Max and the McKesson/Parata RDS. This is the third major study conducted by AlburtyLab examining the issues relating to pharmacy worker exposure.
News of the day
Low-Fat Diet Helps Genetically Predisposed Animals Avoid Liver Cancer
In a study comparing two strains of mice, one susceptible to developing cancer and the other not, researchers found that a high-fat diet predisposed the cancer-susceptible strain to liver cancer, and that by switching to a low-fat diet early in the experiment, the same high-risk mice avoided the malignancy. The switched mice were lean rather than obese and had healthy livers at the end of the study.
Public Health

Green Tea Compound May Block A Key Process In Alzheimer's Development

Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health"s (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem™, a compound made from green tea. TeaMem™ holds promise for preventing and treating Alzheimer"s disease (AD), a disease that the Alzheimer"s Association says today affects as many as 5.2 million Americans. The most recent grant follows two other NIH grants to develop and evaluate TeaMem™ -- a $160,000 grant for 2007-2008 and a $140,000 grant for 2008-2009. The research conducted under these three grants was also supported through matching funds from the Florida High Tech Corridor Matching Grants Research Program. According to Jun Tan, M.D., Ph.D., a professor in the USF Department of Psychiatry and Behavioral Medicine, and one of the grant"s principal investigators, the grant will be used to investigate the role of TeaMem™ in opposition to cleavage of the amyloid precursor protein protelysis (APP) into Abeta peptides and resultant cerebral amyloidosis, a process identified as a key feature in AD pathology. "Our recent findings suggest that strategies that promote non-amyloidogenic/alpha-secretase APP processing may have significant potential for the treatment of AD," said Tan. This SBIR grant, the most recent of three NIH grants, allows the continuing development of TeaMem™ and its evaluation in the test tube (in vitro). The latest grant provides for testing in vitro and in the body (in vivo) using mouse models to evaluate the effects of TeaMem™. Early tests will evaluate TeaMem™ in promoting non-amyloidogenic APP alpha-secretase proteolysis and then examine its therapeutic and preventive effects on AD pathology and cognitive impairment. "We expect to clearly define this non-amyloidogenic mechanism and identify the potential molecular drug targets essential for formulating novel, effective treatments against AD," explained Cyndy D. Sanberg, Ph.D., senior vice president of Natura Therapeutics, Inc. and the other PI on the grant. Tests, including cognitive tests, will use mouse models for oral administration of TeaMem™ to a prophylactic treatment group that will be compared to a second group with AD-like pathology. Groups will be compared for the effect of reducing AD-like pathology and behavioral impairment. The studies, said Tan, could lay the groundwork for AD clinical trials in humans in the near future. In their 2008 report, the Alzheimer"s Association (http://www.alz.org) noted that AD was the nation"s sixth leading cause of death and predicts 10 million baby boomers will develop AD. The direct and indirect costs of AD exceed $148 billion annually, said the Association. Dr. Jun Tan University of South Florida Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009